Biotechnology and Biosimilars' cGMP Training
2017-10-19
Refresher training related to “Biotechnology and Biosimilars” cGMP based on FDA 21 CFR Parts 210, 211, 600 to 680 and other International guidelines was conducted for our Insulin and Eryhthropoietin Plant teams.
The training was highly interactive with lots of real-world examples related to the field.
.jpg)
